May 22, 2020 / 8:06 AM / 3 days ago

BRIEF-Bayer Submits Larotrectinib For Marketing Authorization In Japan

May 22 (Reuters) - BAYER AG:

* SUBMITS LAROTRECTINIB FOR MARKETING AUTHORIZATION IN JAPAN FOR THE TREATMENT OF TRK FUSION CANCER Source text: bit.ly/36kzvNw Further company coverage: (Gdansk Newsroom)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below